The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade
- PMID: 23628461
- PMCID: PMC3690974
- DOI: 10.1016/j.ymgme.2013.03.013
The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade
Abstract
Mucopolysaccharidosis (MPS) VII is a lysosomal storage disease due to deficient activity of β-glucuronidase (GUSB), and results in glycosaminoglycan accumulation. Skeletal manifestations include bone dysplasia, degenerative joint disease, and growth retardation. One gene therapy approach for MPS VII involves neonatal intravenous injection of a gamma retroviral vector expressing GUSB, which results in stable expression in liver and secretion of enzyme into blood at levels predicted to be similar or higher to enzyme replacement therapy. The goal of this study was to evaluate the long-term effect of neonatal gene therapy on skeletal manifestations in MPS VII dogs. Treated MPS VII dogs could walk throughout their lives, while untreated MPS VII dogs could not stand beyond 6 months and were dead by 2 years. Luxation of the coxofemoral joint and the patella, dysplasia of the acetabulum and supracondylar ridge, deep erosions of the distal femur, and synovial hyperplasia were reduced, and the quality of articular bone was improved in treated dogs at 6 to 11 years of age compared with untreated MPS VII dogs at 2 years or less. However, treated dogs continued to have osteophyte formation, cartilage abnormalities, and an abnormal gait. Enzyme activity was found near synovial blood vessels, and there was 2% as much GUSB activity in synovial fluid as in serum. We conclude that neonatal gene therapy reduces skeletal abnormalities in MPS VII dogs, but clinically-relevant abnormalities remain. Enzyme replacement therapy will probably have similar limitations long-term.
Copyright © 2013 Elsevier Inc. All rights reserved.
Figures










Similar articles
-
Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs.Mol Genet Metab. 2004 May;82(1):4-19. doi: 10.1016/j.ymgme.2004.01.015. Mol Genet Metab. 2004. PMID: 15110316
-
The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice.Mol Genet Metab. 2015 Feb;114(2):209-16. doi: 10.1016/j.ymgme.2014.12.305. Epub 2014 Dec 19. Mol Genet Metab. 2015. PMID: 25559179 Free PMC article.
-
The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade.Mol Genet Metab. 2013 Nov;110(3):311-8. doi: 10.1016/j.ymgme.2013.06.015. Epub 2013 Jun 25. Mol Genet Metab. 2013. PMID: 23860311 Free PMC article.
-
Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.J Inherit Metab Dis. 1998 Aug;21(5):575-86. doi: 10.1023/a:1005423222927. J Inherit Metab Dis. 1998. PMID: 9728337 Review.
-
Gene therapy for murine mucopolysaccharidosis type VII.Neuromuscul Disord. 1997 Jul;7(5):352-60. doi: 10.1016/s0960-8966(97)00061-8. Neuromuscul Disord. 1997. PMID: 9267850 Review.
Cited by
-
Therapies for the bone in mucopolysaccharidoses.Mol Genet Metab. 2015 Feb;114(2):94-109. doi: 10.1016/j.ymgme.2014.12.001. Epub 2014 Dec 9. Mol Genet Metab. 2015. PMID: 25537451 Free PMC article. Review.
-
Electrophysiological and Histological Characterization of Rod-Cone Retinal Degeneration and Microglia Activation in a Mouse Model of Mucopolysaccharidosis Type IIIB.Sci Rep. 2015 Nov 26;5:17143. doi: 10.1038/srep17143. Sci Rep. 2015. PMID: 26607664 Free PMC article.
-
Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity.J Clin Invest. 2014 Jan;124(1):311-20. doi: 10.1172/JCI72339. Epub 2013 Dec 16. J Clin Invest. 2014. PMID: 24334460 Free PMC article.
-
Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases.Front Vet Sci. 2020 Mar 11;7:80. doi: 10.3389/fvets.2020.00080. eCollection 2020. Front Vet Sci. 2020. PMID: 32219101 Free PMC article. Review.
-
In vivo direct lentiviral gene therapy improves disease pathology in a mucopolysaccharidosis IVA murine model.Mol Ther Methods Clin Dev. 2025 Jun 16;33(3):101514. doi: 10.1016/j.omtm.2025.101514. eCollection 2025 Sep 11. Mol Ther Methods Clin Dev. 2025. PMID: 40677837 Free PMC article.
References
-
- Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421.
-
- White KK, Harmatz P. Orthopedic management of mucopolysaccharide disease. J Pediatr Rehabil Med. 2010;3:47–56. - PubMed
-
- White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011;50(Suppl 5):v26–V33. - PubMed
-
- Masterson EL, Murphy PG, O'Meara A, Moore DP, Dowling FE, Forgarty EE. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop. 1996;16:731–733. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources